Market Closed -
Nasdaq Helsinki
11:29:33 2024-06-04 am EDT
|
5-day change
|
1st Jan Change
|
2
EUR
|
+0.10%
|
|
-8.68%
|
+26.18%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
471.5
|
477.3
|
250.8
|
124.3
|
170.7
|
-
|
-
|
Enterprise Value (EV)
1 |
417.4
|
401.5
|
189
|
83.08
|
129.9
|
144
|
150.9
|
P/E ratio
|
-20.2
x
|
-22.7
x
|
-11
x
|
-6.1
x
|
-9.99
x
|
-13.8
x
|
-12.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
686
x
|
239
x
|
71.9
x
|
48.4
x
|
19.8
x
|
11.7
x
|
6.63
x
|
EV / Revenue
|
608
x
|
201
x
|
54.2
x
|
32.4
x
|
15.1
x
|
9.86
x
|
5.86
x
|
EV / EBITDA
|
-22.9
x
|
-22.7
x
|
-9.93
x
|
-4.24
x
|
-9.37
x
|
-17.1
x
|
-16.6
x
|
EV / FCF
|
-25.3
x
|
-18.2
x
|
-6.47
x
|
-3.81
x
|
-8.8
x
|
-14.5
x
|
-23.2
x
|
FCF Yield
|
-3.95%
|
-5.5%
|
-15.5%
|
-26.2%
|
-11.4%
|
-6.88%
|
-4.32%
|
Price to Book
|
7.53
x
|
5.65
x
|
2.88
x
|
1.86
x
|
3.63
x
|
4.34
x
|
4.44
x
|
Nbr of stocks (in thousands)
|
66,600
|
72,535
|
78,364
|
78,434
|
85,445
|
-
|
-
|
Reference price
2 |
7.080
|
6.580
|
3.200
|
1.585
|
1.998
|
1.998
|
1.998
|
Announcement Date
|
2/26/21
|
2/22/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.687
|
2
|
3.487
|
2.566
|
8.62
|
14.6
|
25.75
|
EBITDA
1 |
-18.2
|
-17.7
|
-19.03
|
-19.6
|
-13.87
|
-8.425
|
-9.1
|
EBIT
1 |
-19.42
|
-19.7
|
-21.41
|
-22.48
|
-17.2
|
-12.02
|
-13.2
|
Operating Margin
|
-2,827.22%
|
-985%
|
-613.97%
|
-875.92%
|
-199.54%
|
-82.36%
|
-51.26%
|
Earnings before Tax (EBT)
1 |
-19.44
|
-19.69
|
-22.06
|
-20.73
|
-16.55
|
-11.92
|
-13.1
|
Net income
1 |
-19.44
|
-19.7
|
-22.08
|
-20.76
|
-16.58
|
-11.92
|
-13.1
|
Net margin
|
-2,829.84%
|
-985%
|
-633.07%
|
-808.89%
|
-192.34%
|
-81.68%
|
-50.87%
|
EPS
2 |
-0.3500
|
-0.2900
|
-0.2900
|
-0.2600
|
-0.2000
|
-0.1450
|
-0.1600
|
Free Cash Flow
1 |
-16.49
|
-22.09
|
-29.21
|
-21.81
|
-14.76
|
-9.91
|
-6.515
|
FCF margin
|
-2,400.63%
|
-1,104.28%
|
-837.54%
|
-849.86%
|
-171.17%
|
-67.88%
|
-25.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/21
|
2/22/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.475
|
0.66
|
0.76
|
0.89
|
0.85
|
0.986
|
0.744
|
0.78
|
0.641
|
0.401
|
0.602
|
0.98
|
1.09
|
5.95
|
EBITDA
1 |
-4.615
|
-4.8
|
-4.6
|
-5.484
|
-4.19
|
-4.784
|
-4.493
|
-5.372
|
-4.38
|
-5.353
|
-5.748
|
-4.25
|
-3.43
|
-0.44
|
EBIT
1 |
-5.108
|
-5.4
|
-
|
-6.07
|
-4.8
|
-5.43
|
-5.148
|
-6.103
|
-5.102
|
-6.122
|
-6.525
|
-5.09
|
-4.26
|
-1.33
|
Operating Margin
|
-1,075.37%
|
-818.18%
|
-
|
-682.02%
|
-564.71%
|
-550.71%
|
-691.94%
|
-782.44%
|
-795.94%
|
-1,526.68%
|
-1,083.89%
|
-519.39%
|
-390.83%
|
-22.35%
|
Earnings before Tax (EBT)
1 |
-4.512
|
-5.566
|
-
|
-6.055
|
-5.151
|
-5.57
|
-
|
-
|
-4.116
|
-5.331
|
-6.959
|
-5.8
|
-3.3
|
-0.5
|
Net income
1 |
-4.513
|
-5.6
|
-5.3
|
-6.058
|
-5.16
|
-5.568
|
-4.491
|
-6.804
|
-4.122
|
-5.339
|
-6.967
|
-5.09
|
-4.26
|
-0.71
|
Net margin
|
-950.11%
|
-848.48%
|
-697.37%
|
-680.67%
|
-607.06%
|
-564.71%
|
-603.63%
|
-872.31%
|
-643.06%
|
-1,331.42%
|
-1,157.31%
|
-519.39%
|
-390.83%
|
-11.93%
|
EPS
|
-0.0600
|
-0.0800
|
-0.0700
|
-0.0800
|
-0.0700
|
-0.0700
|
-0.0600
|
-0.0900
|
-0.0500
|
-0.0700
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/25/21
|
2/22/22
|
5/24/22
|
8/25/22
|
11/29/22
|
2/28/23
|
5/25/23
|
8/24/23
|
11/22/23
|
2/29/24
|
5/30/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
54.2
|
75.7
|
61.8
|
41.2
|
40.8
|
26.7
|
19.8
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.5
|
-22.1
|
-29.2
|
-21.8
|
-14.8
|
-9.91
|
-6.52
|
ROE (net income / shareholders' equity)
|
-55.1%
|
-26.8%
|
-25.7%
|
-26.9%
|
-25.1%
|
-14.1%
|
-1.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.9400
|
1.160
|
1.110
|
0.8500
|
0.5500
|
0.4600
|
0.4500
|
Cash Flow per Share
2 |
-0.2500
|
-0.2100
|
-0.2600
|
-0.2300
|
-0.1000
|
-0.1000
|
-
|
Capex
1 |
2.34
|
7.74
|
9.13
|
3.81
|
3.5
|
3.1
|
4.25
|
Capex / Sales
|
340.06%
|
386.84%
|
261.7%
|
148.34%
|
40.6%
|
21.23%
|
16.5%
|
Announcement Date
|
2/26/21
|
2/22/22
|
2/28/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
1.998
EUR Average target price
4.25
EUR Spread / Average Target +112.71% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.18% | 186M | | +46.05% | 56.65B | | -6.88% | 39.44B | | +39.19% | 39.03B | | -6.65% | 26.86B | | +12.37% | 26.75B | | -21.01% | 19.03B | | +0.88% | 12.28B | | +24.48% | 12.26B | | +27.04% | 12.04B |
Other Biotechnology & Medical Research
|